Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J; SPCG-5 Study Group.

Scand J Urol Nephrol. 2008;42(3):220-9. doi: 10.1080/00365590801943274.

PMID:
18432528
2.

Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E; Scandinavian Prostatic Cancer Group.

Scand J Urol Nephrol. 2002;36(6):405-13.

PMID:
12623503
3.

Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.

Hedlund PO, Johansson R, Damber JE, Hagerman I, Henriksson P, Iversen P, Klarskov P, Mogensen P, Rasmussen F, Varenhorst E; SPCG-5 STUDY GROUP.

Scand J Urol Nephrol. 2011 Nov;45(5):346-53. doi: 10.3109/00365599.2011.585820. Epub 2011 May 31.

PMID:
21627403
5.

Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.

Spetz AC, Hammar M, Lindberg B, Spångberg A, Varenhorst E; Scandinavian Prostatic Cancer Group-5 Trial Study.

J Urol. 2001 Aug;166(2):517-20.

PMID:
11458057
8.
9.

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):327-33. doi: 10.1016/j.ijrobp.2008.04.075. Epub 2008 Aug 15.

PMID:
18707821
10.

Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.

Demanes DJ, Brandt D, Schour L, Hill DR.

Am J Clin Oncol. 2009 Aug;32(4):342-7. doi: 10.1097/COC.0b013e31818cd277.

PMID:
19398902
12.

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.

James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.

Eur Urol. 2009 May;55(5):1112-23. doi: 10.1016/j.eururo.2008.11.002. Epub 2008 Nov 29.

PMID:
19042080
13.

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L.

J Clin Oncol. 2006 Apr 20;24(12):1868-76.

PMID:
16622261
14.

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV.

J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.

PMID:
18172188
15.

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, van Velthoven RF, Debois M, Collette L; Members of the EORTC Genito-Urinary Group.

Eur Urol. 2004 Apr;45(4):457-64.

PMID:
15041109
16.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
18.

Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.

Henriksson P, Carlström K, Pousette A, Gunnarsson PO, Johansson CJ, Eriksson B, Altersgård-Brorsson AK, Nordle O, Stege R.

Prostate. 1999 Jul 1;40(2):76-82.

PMID:
10386467
19.

Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up.

Bañez LL, Blake GW, McLeod DG, Crawford ED, Moul JW.

BJU Int. 2009 Aug;104(3):310-4. doi: 10.1111/j.1464-410X.2009.08400.x. Epub 2009 Feb 23.

20.

The role of parenteral polyestradiol phosphate in the treatment of advanced prostatic cancer on the threshold of the new millennium.

Mikkola A, Ruutu M, Aro J, Rannikko S, Salo J.

Ann Chir Gynaecol. 1999;88(1):18-21. Review.

PMID:
10230677

Supplemental Content

Support Center